Health & Fitness
Thu, February 9, 2012
BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its 2011 financial results on Wednesday, February 15, 2012 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET.
To participate in the conference call, dial (888) 268-4176 and use passcode 16704407. International callers may dial (617) 597-5493, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investorsa calendar of events page on the NPS website, [ http://www.npsp.com ].
If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 34627817 until midnight ET, February 29, 2012. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natparaa" (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPSa earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Janssen Pharmaceuticals, Inc.
